Fig. 4From: Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoterEGR1 RNAi suppressed the growth of glioma xenograft tumor in vivo. a siEGR1-U251 cells (5 × 106) and NC-U251 (5 × 106) cells were inoculated subcutaneously into armpit of BALB/C nude mice, all of the mice examined developed tumors at 50th day. In NC-U251SC (1 × 106) group, all mice developed xenograft tumors at 40th day. In contrast, in siEGR1-U251SCL (1 × 106) group, only 3 mice developed xenograft tumors at 40th day. b Mice were euthanized and implanting tumors were harvested, and examined. siEGR1-U251-derived tumors showed smaller tumor volume compared with the volume of NC-U251-derived tumors, P < 0.05 *. c siEGR1-U251SLC-derived tumors also showed smaller tumor volume compared with the volume of NC-U251SLC-derived tumors, P < 0.01 **. d H&E staining and GFAP immunohistochemistry of siEGR1-U251-derived tumors and NC-U251-derived tumors. e E. Ki-67, EGR1, CCND1 staining of subcutaneous tumors in NC-U251 and siEGR1-U251 groups. Scale bar = 50 μmBack to article page